Teva- Pharmaceutical Industries Ltd. - ADR
TEVA
Market Cap$19.4B
Close$
Earnings Call Q4 2024
January 29, 2025 - AI Summary
Strong Revenue Growth: Teva reported robust revenue of $16.5 billion for 2024, marking a 9% increase year-over-year (YOY). This growth was driven primarily by innovative products AUSTEDO (34% growth), AJOVY (18% growth), and UZEDY (exceeding $100 million in revenue by reaching $117 million), showcasing effective execution on their growth strategy.
Innovative Product Forecasts: For 2025, Teva aims for significant contributions from its key products, projecting AUSTEDO revenues to be between $1.9 billion to $2 billion, AJOVY over $600 million, and UZEDY $160 million. This indicates confidence in continuing momentum in their innovative drug portfolio.
Earnings and EBITDA Expectations: The non-GAAP earnings per share (EPS) is forecasted at $2.35 to $2.65 for 2025, with non-GAAP adjusted EBITDA expected between $4.5 billion and $5 billion. However, this is not anticipated to significantly improve from 2024 levels, indicating potential operational challenges despite revenue growth.
Exclusive for Stockcircle Pro members
Sign up
$2.61
85.1% downside
Current Fair Value
85.1% downsideOvervalued by 85.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.40 Billion |
|---|---|
| Enterprise Value | $34.18 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.45 |
| Beta | 0.63 |
| Outstanding Shares | 1,133,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -12.66 |
|---|---|
| PEG | 1.96 |
| Price to Sales | 1.25 |
| Price to Book Ratio | 1.09 |
| Enterprise Value to Revenue | 2.04 |
| Enterprise Value to EBIT | 14.57 |
| Enterprise Value to Net Income | -35 |
| Total Debt to Enterprise | 0.53 |
| Debt to Equity | 3.36 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Teva- Pharmaceutical Industries Ltd.
CEO: Kaare Schultz